Debyani Chakravarty1, Jianjiong Gao1, Sarah M Phillips1, Ritika Kundra1, Hongxin Zhang1, Jiaojiao Wang1, Julia E Rudolph1, Rona Yaeger1, Tara Soumerai1, Moriah H Nissan1, Matthew T Chang1, Sarat Chandarlapaty1, Tiffany A Traina1, Paul K Paik1, Alan L Ho1, Feras M Hantash1, Andrew Grupe1, Shrujal S Baxi1, Margaret K Callahan1, Alexandra Snyder1, Ping Chi1, Daniel Danila1, Mrinal Gounder1, James J Harding1, Matthew D Hellmann1, Gopa Iyer1, Yelena Janjigian1, Thomas Kaley1, Douglas A Levine1, Maeve Lowery1, Antonio Omuro1, Michael A Postow1, Dana Rathkopf1, Alexander N Shoushtari1, Neerav Shukla1, Martin Voss1, Ederlinda Paraiso1, Ahmet Zehir1, Michael F Berger1, Barry S Taylor1, Leonard B Saltz1, Gregory J Riely1, Marc Ladanyi1, David M Hyman1, José Baselga1, Paul Sabbatini1, David B Solit1, Nikolaus Schultz1. 1. , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , , Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Department of R&D and Bioinformatics, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract
PURPOSE: With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, there is an urgent need for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision oncology knowledge base. METHODS: OncoKB annotates the biological and oncogenic effect and the prognostic and predictive significance of somatic molecular alterations. Potential treatment implications are stratified by the level of evidence that a specific molecular alteration is predictive of drug response based on US Food and Drug Administration (FDA) labeling, National Comprehensive Cancer Network (NCCN) guidelines, disease-focused expert group recommendations and the scientific literature. RESULTS: To date, over 3000 unique mutations, fusions, and copy number alterations in 418 cancer-associated genes have been annotated. To test the utility of OncoKB, we annotated all genomic events in 5983 primary tumor samples in 19 cancer types. Forty-one percent of samples harbored at least one potentially actionable alteration, of which 7.5% were predictive of clinical benefit from a standard treatment. OncoKB annotations are available through a public web resource (http://oncokb.org/) and are also incorporated into the cBioPortal for Cancer Genomics to facilitate the interpretation of genomic alterations by physicians and researchers. CONCLUSION: OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patient tumors with the goal of supporting optimal treatment decisions.
PURPOSE: With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, there is an urgent need for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision oncology knowledge base. METHODS: OncoKB annotates the biological and oncogenic effect and the prognostic and predictive significance of somatic molecular alterations. Potential treatment implications are stratified by the level of evidence that a specific molecular alteration is predictive of drug response based on US Food and Drug Administration (FDA) labeling, National Comprehensive Cancer Network (NCCN) guidelines, disease-focused expert group recommendations and the scientific literature. RESULTS: To date, over 3000 unique mutations, fusions, and copy number alterations in 418 cancer-associated genes have been annotated. To test the utility of OncoKB, we annotated all genomic events in 5983 primary tumor samples in 19 cancer types. Forty-one percent of samples harbored at least one potentially actionable alteration, of which 7.5% were predictive of clinical benefit from a standard treatment. OncoKB annotations are available through a public web resource (http://oncokb.org/) and are also incorporated into the cBioPortal for Cancer Genomics to facilitate the interpretation of genomic alterations by physicians and researchers. CONCLUSION: OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic mutations and structural alterations present in patienttumors with the goal of supporting optimal treatment decisions.
Authors: Rena M Conti; Arielle C Bernstein; Victoria M Villaflor; Richard L Schilsky; Meredith B Rosenthal; Peter B Bach Journal: J Clin Oncol Date: 2013-02-19 Impact factor: 44.544
Authors: Patrick C Ma; Ramasamy Jagadeeswaran; Simha Jagadeesh; Maria S Tretiakova; Vidya Nallasura; Edward A Fox; Mark Hansen; Erik Schaefer; Katsuhiko Naoki; Alan Lader; William Richards; David Sugarbaker; Aliya N Husain; James G Christensen; Ravi Salgia Journal: Cancer Res Date: 2005-02-15 Impact factor: 12.701
Authors: Cynthia X Ma; Jingqin Luo; Michael Naughton; Foluso Ademuyiwa; Rama Suresh; Malachi Griffith; Obi L Griffith; Zachary L Skidmore; Nicholas C Spies; Avinash Ramu; Lee Trani; Timothy Pluard; Gayathri Nagaraj; Shana Thomas; Zhanfang Guo; Jeremy Hoog; Jing Han; Elaine Mardis; Craig Lockhart; Matthew J Ellis Journal: Clin Cancer Res Date: 2015-11-12 Impact factor: 12.531
Authors: Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb Journal: Cell Date: 2007-12-14 Impact factor: 41.582
Authors: Sara E Patterson; Rangjiao Liu; Cara M Statz; Daniel Durkin; Anuradha Lakshminarayana; Susan M Mockus Journal: Hum Genomics Date: 2016-01-16 Impact factor: 4.639
Authors: Rona Yaeger; Walid K Chatila; Marla D Lipsyc; Jaclyn F Hechtman; Andrea Cercek; Francisco Sanchez-Vega; Gowtham Jayakumaran; Sumit Middha; Ahmet Zehir; Mark T A Donoghue; Daoqi You; Agnes Viale; Nancy Kemeny; Neil H Segal; Zsofia K Stadler; Anna M Varghese; Ritika Kundra; Jianjiong Gao; Aijazuddin Syed; David M Hyman; Efsevia Vakiani; Neal Rosen; Barry S Taylor; Marc Ladanyi; Michael F Berger; David B Solit; Jinru Shia; Leonard Saltz; Nikolaus Schultz Journal: Cancer Cell Date: 2018-01-08 Impact factor: 31.743
Authors: Craig M Bielski; Mark T A Donoghue; Mayur Gadiya; Aphrothiti J Hanrahan; Helen H Won; Matthew T Chang; Philip Jonsson; Alexander V Penson; Alexander Gorelick; Christopher Harris; Alison M Schram; Aijazuddin Syed; Ahmet Zehir; Paul B Chapman; David M Hyman; David B Solit; Kevin Shannon; Sarat Chandarlapaty; Michael F Berger; Barry S Taylor Journal: Cancer Cell Date: 2018-11-01 Impact factor: 31.743
Authors: Winston Wong; Maeve A Lowery; Michael F Berger; Yelena Kemel; Barry Taylor; Ahmet Zehir; Preethi Srinivasan; Chaitanya Bandlamudi; Joanne Chou; Marinela Capanu; Anna Varghese; Kenneth H Yu; Christine A Iacobuzio-Donahue; Jinru Shia; David S Klimstra; William R Jarnagin; Zsofia K Stadler; Eileen M O'Reilly Journal: Cancer Date: 2019-01-08 Impact factor: 6.860
Authors: Yang Liu; Nilay S Sethi; Toshinori Hinoue; Barbara G Schneider; Andrew D Cherniack; Francisco Sanchez-Vega; Jose A Seoane; Farshad Farshidfar; Reanne Bowlby; Mirazul Islam; Jaegil Kim; Walid Chatila; Rehan Akbani; Rupa S Kanchi; Charles S Rabkin; Joseph E Willis; Kenneth K Wang; Shannon J McCall; Lopa Mishra; Akinyemi I Ojesina; Susan Bullman; Chandra Sekhar Pedamallu; Alexander J Lazar; Ryo Sakai; Vésteinn Thorsson; Adam J Bass; Peter W Laird Journal: Cancer Cell Date: 2018-04-02 Impact factor: 31.743
Authors: Michael D Nyquist; Alexandra Corella; Ilsa Coleman; Navonil De Sarkar; Arja Kaipainen; Gavin Ha; Roman Gulati; Lisa Ang; Payel Chatterjee; Jared Lucas; Colin Pritchard; Gail Risbridger; John Isaacs; Bruce Montgomery; Colm Morrissey; Eva Corey; Peter S Nelson Journal: Cell Rep Date: 2020-05-26 Impact factor: 9.423
Authors: Michelle J Lee; Jean L Koff; Jeffrey M Switchenko; C Ileen Jhaney; R Andrew Harkins; Sharvil P Patel; Sandeep S Dave; Christopher R Flowers Journal: Cancer Date: 2020-05-29 Impact factor: 6.860
Authors: Raja R Narayan; Debra A Goldman; Mithat Gonen; Jonathan Reichel; Kety H Huberman; Sandeep Raj; Agnes Viale; Nancy E Kemeny; Peter J Allen; Vinod P Balachandran; Michael I D'Angelica; Ronald P DeMatteo; Jeffrey A Drebin; William R Jarnagin; T Peter Kingham Journal: Ann Surg Oncol Date: 2019-01-31 Impact factor: 5.344
Authors: Bridget K Marcellino; Noushin Farnoud; Bruno Cassinat; Min Lu; Emanuelle Verger; Erin McGovern; Minal Patel; Juan Medina-Martinez; Max Fine Levine; Juanes E Arango Ossa; Yangyu Zhou; Heidi Kosiorek; Meenakshi Mehrotra; Jane Houldsworth; Amylou Dueck; Michael Rossi; John Mascarenhas; Jean-Jacques Kiladjian; Raajit K Rampal; Ronald Hoffman Journal: Blood Adv Date: 2020-11-24